Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase I Pipeline Programs

First-in-human and early clinical safety studies in Phase I.

Programs 4,713
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 4,713 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.

Top sponsors

Pipeline programs

Page 63 of 99

  1. Nivolumab

    Jazz Pharmaceuticals Ireland Limited

    Small-cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  2. Nivolumab

    Atrium Therapeutics

    Brain and Nervous System

    phase 1 small molecule completed

    1 trial

  3. Nivolumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Effect of Drug

    phase 1 small molecule active

    1 trial

  4. Nizatidine

    ADIAL PHARMACEUTICALS, INC.

    Gastroparesis

    phase 1 small molecule completed

    1 trial

  5. No Intervention

    Takeda

    Rheumatoid Arthritis

    phase 1 other completed

    1 trial

  6. NoV GI.1/GII.4 Bivalent VLP Vaccine

    Takeda

    Gastroenteritis

    phase 1 mab completed

    1 trial

  7. Nomlabofusp

    Larimar Therapeutics

    Friedreich Ataxia

    phase 1 small molecule terminated

    1 trial

  8. Norethindrone/Ethinyl Estradiol

    Teva Pharma GmbH

    Bioequivalence

    phase 1 small molecule completed

    1 trial

  9. Norethindrone/Ethinyl Estradiol

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    1 trial

  10. Normal Saline (NS) .9% 10 mL Injection

    Blackmores Limited

    Ovarian Failure

    phase 1 small molecule active

    1 trial

  11. Norovirus

    United Therapeutics Europe Ltd

    Healthy Adults

    phase 1 mab completed

    1 trial

  12. Not applicable

    Chiesi Farmaceutici S.p.A

    Non-cystic fibrosis bronchiectasis

    phase 1 other active

    1 trial

  13. Novel Supplement Based Therapy

    Atrium Therapeutics

    Small Intestinal Bacterial Overgrowth

    phase 1 other terminated

    1 trial

  14. Novel restraint

    Lxo Ireland Designated Activity Company

    Acute Respiratory Failure

    phase 1 other completed

    1 trial

  15. O2P-001

    BRIGHT MINDS BIOSCIENCES INC.

    Acute Pain

    phase 1 small molecule active

    1 trial

  16. O3R-5671-CL-101

    Lacuna Pharma Pty Ltd

    Inflammatory bowel diseases and psoriasis.

    phase 1 other active

    1 trial

  17. OD-07656

    Odyssey Therapeutics

    Inflammatory Bowel Diseases

    phase 1 small molecule completed

    1 trial

  18. ODSH

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 1 small molecule completed

    1 trial

  19. ODSH at 0.125 mg/kg/h

    Jazz Pharmaceuticals Ireland Limited

    Protein Losing Enteropathy

    phase 1 small molecule terminated

    1 trial

  20. ODYSSEY

    Advanced Accelerator Applications

    Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes, Ineligible for Intensiveor New Generation Targeted Therapy

    phase 1 other active

    1 trial

  21. OKI-179

    OnKure Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  22. OKI-219

    OnKure Therapeutics

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  23. OKI-219-101

    OnKure Therapeutics

    Advanced Solid Tumors, Advanced Breast Cancer

    phase 1 other active

    1 trial

  24. OKN4395

    Chongqing Precision Biotech Co., Ltd

    Solid Tumours

    phase 1 small molecule active

    1 trial

  25. OMP-131R10

    Mereo BioPharma Group plc

    Advanced Relapsed Tumors

    phase 1 small molecule completed

    1 trial

  26. OMP-18R5

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 mab completed

    1 trial

  27. OMP-21M18

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  28. OMP-21M18

    Mereo BioPharma Group plc

    Colorectal Cancer

    phase 1 small molecule completed

    1 trial

  29. OMP-305B83

    Mereo BioPharma Group plc

    Advanced Solid Tumor Malignancies

    phase 1 small molecule completed

    1 trial

  30. OMP-305B83

    Mereo BioPharma Group plc

    Metastatic Colorectal Cancer

    phase 1 small molecule terminated

    1 trial

  31. OMP-305B83

    Mereo BioPharma Group plc

    Cancer Ovaries

    phase 1 small molecule completed

    1 trial

  32. OMP-313M32

    Mereo BioPharma Group plc

    Locally Advanced Cancer

    phase 1 small molecule terminated

    1 trial

  33. OMP-336B11

    Mereo BioPharma Group plc

    Locally Advanced Malignant Neoplasm

    phase 1 small molecule terminated

    1 trial

  34. OMP-52M51

    Mereo BioPharma Group plc

    Relapsed or Refractory Solid Tumors

    phase 1 small molecule completed

    1 trial

  35. OMP-52M51

    Mereo BioPharma Group plc

    Relapsed or Refractory Lymphoid Malignancies

    phase 1 small molecule completed

    1 trial

  36. OMP-54F28

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 mab completed

    1 trial

  37. OMP-54F28 with Sorafenib

    Mereo BioPharma Group plc

    Hepatocellular Cancer

    phase 1 small molecule completed

    1 trial

  38. OMP-54F28, Nab-Paclitaxel and Gemcitabine

    Mereo BioPharma Group plc

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  39. OMP-54F28, Paclitaxel and Carboplatin

    Mereo BioPharma Group plc

    Ovarian Cancer

    phase 1 small molecule completed

    1 trial

  40. OMP-59R5

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  41. OMTX705-001

    Lacuna Pharma Pty Ltd

    Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).

    phase 1 other active

    1 trial

  42. OMTX705-006 Phase 1b

    Lacuna Pharma Pty Ltd

    Advanced/Metastatic Pancreatic Adenocarcinoma

    phase 1 other active

    1 trial

  43. ONC206

    Jazz Pharmaceuticals Ireland Limited

    Diffuse Midline Glioma (DMG)

    phase 1 small molecule active

    1 trial

  44. ONC206

    Jazz Pharmaceuticals Ireland Limited

    Central Nervous System Neoplasms

    phase 1 small molecule active

    1 trial

  45. ONC206 Powder

    AXIM BIOTECHNOLOGIES, INC.

    Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors

    phase 1 small molecule active

    1 trial

  46. ONO-4578

    Ono Pharmaceutical Co.,

    Metastatic Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  47. ONX-0801

    United Therapeutics Europe Ltd

    Solid Tumours

    phase 1 small molecule completed

    1 trial

  48. OP-3136

    Olema Pharmaceuticals

    Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many Phase I pipeline programs are in the directory?

4,713 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.